Key facts
| Price (PPV) | 7,735 MAD |
|---|---|
| Dispensing status | Schedule A — prescription only |
| Composition (DCI) | trifluridinetipiracil |
| Class | Antineoplastic agents |
| ATC code | L01BC59 |
| Manufacturer | SERVIER MAROC |
| Presentation | Boite de 20 (Trifluridine (20mg) , Tipiracil (8.19 mg)) |
| Hospital price | 7,551 MAD |
| Data collected on | 9/8/2026 |
Indications
Cancer colorectal Lonsurf est indiqué dans le traitement des patients adultes atteints d'un cancer colorectal métastatique (CCRm) qui ont été précédemment traités par les traitements disponibles incluant une chimiothérapie à base de fluoropyrimidine, d'oxaliplatine et d'irinotecan, un traitement par anti-VEGF et ainsi qu'un traitement par anti-EGFR chez les patients avec un statut KRAS non muté (type sauvage). Cancer gastrique Lonsurf est indiqué dans le traitement des patients adultes atteints d'un cancer gastrique métastatique, y compris un adénocarcinome de la jonction gastro-œsophagienne. Les patients doivent avoir été préalablement traités par au moins deux chimiothérapies à base de fluoropyrimidine, de platine et de taxane ou d'irinotecan et, si approprié, par un traitement ciblé HER2/neu.
Find an open pharmacy
On-call pharmacies near you
Same-strength alternatives — cheapest first
Lonsurf 20 mg / 8.19 mg (SERVIER MAROC) contains the same active substance as Lonsurf 20 mg / 8.19 mg (Trifluridine | Tipiracil) at the same strength, but in a different pack: Boite de 60 at 21,165 MAD, i.e. 352.75 MAD per unit against 386.75 MAD for Lonsurf 20 mg / 8.19 mg. The public sale price is set by the Ministry of Health: it is identical in every pharmacy.
| Product | Manufacturer | Pack | PPV | Unit price |
|---|---|---|---|---|
| Lonsurf 20 mg / 8.19 mg | SERVIER MAROC | Boite de 60 | 21,165 MAD | 352.75 / unit |
Substituting a generic is the pharmacist's decision; for medicines listed in schedules A, B and C it still requires a prescription. Public sale prices published by the Directorate of Medicines and Pharmacy, recorded on 9/8/2026.
About Lonsurf 20 mg / 8.19 mg
Lonsurf 20 mg / 8.19 mg belongs to the antineoplastic agents therapeutic class. In Morocco, this drug is marketed by SERVIER MAROC and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of Lonsurf 20 mg / 8.19 mg, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about Lonsurf 20 mg / 8.19 mg
Answers to common questions from Moroccan patients about this drug.